NYSE
ABT

Abbott Laboratories

Medical Devices
Healthcare

Prices are adjusted according to historical splits.

Abbott Laboratories Stock Price

Vitals

Today's Low:
$101.6
Today's High:
$102.92
Open Price:
$102.37
52W Low:
$92.8297
52W High:
$122.6629
Prev. Close:
$102.45
Volume:
3520870

Company Statistics

Market Cap.:
$173.76 billion
Book Value:
21.111
Revenue TTM:
$43.65 billion
Operating Margin TTM:
20.24%
Gross Profit TTM:
$24.58 billion
Profit Margin:
15.88%
Return on Assets TTM:
7.38%
Return on Equity TTM:
19.01%

Company Profile

Abbott Laboratories had its IPO on 1978-01-13 under the ticker symbol ABT.

The company operates in the Healthcare sector and Medical Devices industry. Abbott Laboratories has a staff strength of 115,000 employees.

Stock update

Shares of Abbott Laboratories opened at $102.37 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $101.6 - $102.92, and closed at $102.4.

This is a -0.05% slip from the previous day's closing price.

A total volume of 3,520,870 shares were traded at the close of the day’s session.

In the last one week, shares of Abbott Laboratories have slipped by -0.44%.

Abbott Laboratories's Key Ratios

Abbott Laboratories has a market cap of $173.76 billion, indicating a price to book ratio of 5.4377 and a price to sales ratio of 4.2019.

In the last 12-months Abbott Laboratories’s revenue was $43.65 billion with a gross profit of $24.58 billion and an EBITDA of $12.10 billion. The EBITDA ratio measures Abbott Laboratories's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Abbott Laboratories’s operating margin was 20.24% while its return on assets stood at 7.38% with a return of equity of 19.01%.

In Q4, Abbott Laboratories’s quarterly earnings growth was a negative -47.2% while revenue growth was a negative 12%.

Abbott Laboratories’s PE and PEG Ratio

Forward PE
25.1256
Trailing PE
25.5703
PEG
18.7638

Its diluted EPS in the last 12-months stands at $3.91 per share while it has a forward price to earnings multiple of 25.1256 and a PEG multiple of 18.7638. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Abbott Laboratories’s profitability.

Abbott Laboratories stock is trading at a EV to sales ratio of 4.4525 and a EV to EBITDA ratio of 15.1995. Its price to sales ratio in the trailing 12-months stood at 4.2019.

Abbott Laboratories stock pays annual dividends of $1.92 per share, indicating a yield of 1.99% and a payout ratio of 35.96%.

Balance sheet and cash flow metrics

Total Assets
$74.44 billion
Total Liabilities
$15.49 billion
Operating Cash Flow
$-632000000.00
Capital Expenditure
$610 million
Dividend Payout Ratio
35.96%

Abbott Laboratories ended 2024 with $74.44 billion in total assets and $0 in total liabilities. Its intangible assets were valued at $74.44 billion while shareholder equity stood at $36.69 billion.

Abbott Laboratories ended 2024 with $0 in deferred long-term liabilities, $15.49 billion in other current liabilities, 24709000000.00 in common stock, $41.77 billion in retained earnings and $22.80 billion in goodwill. Its cash balance stood at $9.88 billion and cash and short-term investments were $10.17 billion. The company’s total short-term debt was $2,251,000,000 while long-term debt stood at $14.52 billion.

Abbott Laboratories’s total current assets stands at $25.22 billion while long-term investments were $766.00 million and short-term investments were $288.00 million. Its net receivables were $6.22 billion compared to accounts payable of $4.61 billion and inventory worth $6.17 billion.

In 2024, Abbott Laboratories's operating cash flow was $-632000000.00 while its capital expenditure stood at $610 million.

Comparatively, Abbott Laboratories paid $0.36 in dividends in 2024.

Other key metrics

Current Trading Price
$102.4
52-Week High
$122.6629
52-Week Low
$92.8297
Analyst Target Price
$123.5

Abbott Laboratories stock is currently trading at $102.4 per share. It touched a 52-week high of $122.6629 and a 52-week low of $122.6629. Analysts tracking the stock have a 12-month average target price of $123.5.

Its 50-day moving average was $106.46 and 200-day moving average was $105.67 The short ratio stood at 2.83 indicating a short percent outstanding of 0%.

Around 74% of the company’s stock are held by insiders while 7638.1% are held by institutions.

Frequently Asked Questions About Abbott Laboratories

The stock symbol (also called stock or share ticker) of Abbott Laboratories is ABT

The IPO of Abbott Laboratories took place on 1978-01-13

Similar Industry Stocks (Medical Devices)

Last Price
Chg
Chg%
$22.99
0.01
+0.04%
Kopran Limited (KOPRAN)
$213.85
-17.95
-7.74%
$157.8
-13.15
-7.69%
$45.47
-0.85
-1.84%
HLV LIMITED (HLVLTD)
$17.82
-1.35
-7.04%
Engie SA (ENGQF)
$16.33
0.26
+1.62%
$241.55
-19.45
-7.45%

Most Active

Last Price
Chg
Chg%
Amyris Inc (AMRS)
$0.14
0.07
+100%
$0.12
0.04
+45.29%
$0.96
0.05
+5.4%
$1.34
-0.35
-20.71%
Humbl Inc (HMBL)
$0
0
0%

Top Gainers

Last Price
Chg
Chg%
$0
0
+172200%
$0
0
+51200%
$283
280.03
+9428.62%
$11.2
10.57
+1667.68%
Latch Inc (LTCHW)
$0.01
-0.03
+1550%

Top Losers

Last Price
Chg
Chg%
$0.19
-123.15
-99.85%
$0
-0.11
-99.55%
$0
-0
-97.96%
$0
-0.01
-93.94%
$0.01
-0.06
-92.24%

About

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière’s disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.

Address

100 Abbott Park Road, North Chicago, IL, United States, 60064-6400